MOH · Molina Healthcare
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $242.88
Note written ·
Price against the kill line
8.9% clear of its kill line on the 17 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 17 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $242.88, on record since 10 November 2026. The shares are up 10.0% since the close; the S&P 500 is down 4.5% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $242.88, the highest close of the last 126 sessions (13 July 2026), would show the shares leading the S&P 500 and prove this call wrong.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 22 October 2026; valuation at the 17 November 2026 close
- Net income, latest quarter ($M)
- 38.0
- Net income, four quarters ($M)
- −48.0
- Shareholders' equity ($M)
- 4,155
- Price to book value (×)
- 2.8
- Revenue, latest quarter ($M)total revenues, including investment gains and losses
- 11,082
- Revenue, change on a year (%)
- −3.4
- Market value ($M)
- 11,547
Molina Healthcare is an insurer: net cash, enterprise value and free cash flow are not shown, because a bank's or insurer's cash and investments back its deposits and policies.
All filed numbers
What Molina Healthcare reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 11,082 | −3.4 | 12.3 | 1.0 |
| first filed | 10,874 | −4.8 | 13.2 | 1.3 |
| first filed | 10,796 | −3.1 | 14.1 | 0.8 |
| first filed | 11,375 | +8.3 | 10.9 | −1.4 |
| first filed | 11,477 | +11.0 | 12.5 | 1.2 |
| first filed | 11,427 | +15.7 | 14.0 | 3.3 |
| Pre-tax income ($M) | 53.0 |
| Net income ($M) four quarters: −48.0 | 38.0 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | −1.9 |
| Operating cash flow ($M) | 331 |
| Capital spending ($M) | Not available |
| Free cash flow ($M) | Not meaningful |
Not meaningful: a bank's or insurer's operating cash flow moves with its deposits, loans and policy reserves, so it is not cash free for its owners.
| Cash and short-term investments ($M) | 8,579 |
| Debt ($M) non-current long-term debt | 3,771 |
| Net cash, cash less debt ($M) | Not meaningful |
| Deferred revenue ($M) +12.3% on a year | 82.0 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 3,359 |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 4,155 |
Not meaningful: a bank's or insurer's cash and investments back its deposits and policies.
| Market value ($M) | 11,547 |
| Enterprise value, market value plus net debt ($M) | Not meaningful |
| Enterprise value to sales (×) | Not meaningful |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 2.8 |
| Free-cash-flow yield (%) | Not meaningful |
Not meaningful: a bank's or insurer's cash and investments back its deposits and policies.
Not meaningful: a bank's or insurer's operating cash flow moves with its deposits, loans and policy reserves, so it is not cash free for its owners.
Short interest (FINRA, settled 30 October 2026, published 10 November 2026): 5.6% of shares outstanding sold short, 2.9 days of average trading to cover, −2.5% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 days | Not available yet | Not available yet |
| 12 months | Not available yet | Not available yet |
The thesis
Molina Healthcare's recovery case is intact but unproven. The company reaffirmed full-year adjusted earnings per share (EPS) of at least $5.25 on 21 October 2026, yet medical costs stay above 92% of premiums. Fourth-quarter Florida start-up costs and 2027 Medicaid rates settle whether the earnings floor holds.
The shares closed at $203.35 on 9 November 2026, 16.3% below the $242.88 52-week high, with a 14-day relative strength index (RSI) of 39.5 and a three-month change of −1.3% (adjusted daily closes). The close on 27 October 2026 was $199.46. In between, Trefis reported on 5 November 2026 that the shares rose 8.9% on 4 November 2026 as midterm election results lifted large Medicaid insurers; Centene gained 12.6% that day. A STAT News report dated 10 November 2026 says Democratic state wins make Medicaid expansion a possibility for more than a million people. The story is well known: the guidance floor is well known, analysts reset targets within two sessions of the 21 October 2026 report, and the next hard test is the early-2027 report.
Bullish and bearish views on Molina Healthcare, Inc.
The bull case on Molina Healthcare, Inc. (MOH), in brief: guidance held after a beat. The bear case: earnings are roughly half of last year's.
Bull case
- Guidance held after a beat. Molina reported third-quarter adjusted EPS of $0.89 against a $0.74 estimate on 21 October 2026. It reaffirmed adjusted EPS of at least $5.25, GAAP EPS of at least $2.38 and premium revenue of about $42 billion (Form 8-K).
- Management sees Medicaid margins turning. CEO Joseph Zubretsky said on 21 October 2026 that medical cost trend appears to be plateauing at elevated levels and that strong 2027 rate updates suggest "the beginning of the turn in Medicaid margins". A Molina executive said on 22 October 2026 that preliminary 2027 building blocks exceed $9.50 of adjusted EPS without better legacy Medicaid margins.
- Marketplace came in on plan. The third-quarter Marketplace medical cost ratio was 92.5%, which Molina described as in line with normal seasonality. Marketplace was the segment that broke the July forecast.
- Balance sheet has room. Parent-company cash and investments were about $608 million on 30 September 2026, against $223 million on 31 December 2025. Molina repurchased no common stock in the first nine months of 2026 (Form 8-K).
- Policy backdrop turned friendlier. Medicaid insurers rallied on 4 November 2026 after the midterm elections (Trefis, 5 November 2026). Medicaid was 71.0% of Molina's 2025 revenue, so state expansion decisions bear directly on its membership outlook.
Bear case
- Earnings are roughly half of last year's. Third-quarter GAAP net income was $38 million, or $0.73 per share, down 52%. Adjusted net income was $46 million, or $0.89 per share, down 53%. Premium revenue was $10.457 billion, down 4% (company results, 21 October 2026).
- Medical costs are still above 92%. Third-quarter medical cost ratios, the share of premiums paid out as care, were 93.0% in Medicaid, 93.0% in Medicare and 92.9% overall, against 92.6% overall a year earlier.
- Fourth-quarter drags are built in. Guidance includes a $1.50-per-share loss from starting the new Florida Medicaid contract and a $1.00-per-share loss from the traditional Medicare Advantage prescription drug product, which Molina exits for 2027 (Form 8-K, 21 October 2026).
- The 2027 outlook shrank. A Molina executive said on 22 October 2026 that preliminary 2027 premium is now at least $45 billion, down from $46.5 billion. On the 23 July 2026 call, management had described 2027 earnings power above $10 per share.
- The election move may not carry policy. Trefis gave no specific policy change behind the 4 November 2026 jump. Expansion in a few states would add members over years, while redeterminations start in December 2026.
Price setup
The shares closed at $203.35 on 9 November 2026, above the $188 level that gave way on 1 October 2026 and 16.3% under the $242.88 52-week high. An RSI of 39.5 shows the shares have faded since the 4 November 2026 spike rather than extended it.
Analyst targets sit around the price. After the report, J.P. Morgan (Neutral) and UBS (Neutral) set $225, RBC (Sector Perform) $222, Morgan Stanley (Equal-weight) $192 and Barclays (Underweight) $178 (analyst notes, 23 October to 27 October 2026). No post-report rating change is visible in search results dated after 27 October 2026.
Crowding evidence is thin. The shares are well below their high, the next earnings date is about three months away, and SEC Form 4 insider sales or share issuance into strength are not visible. Sector-wide moves such as the 4 November 2026 election day show the shares trade with Centene and other Medicaid insurers.
Molina filed a Form 8-K on 6 November 2026 at 4:19 pm Eastern. Its content could not be retrieved, so it is not part of this read.
Catalysts ahead
- ~1 December 2026 (est.): Twice-a-year Medicaid eligibility redeterminations begin (December 2026). Membership attrition faster than planned would weigh on 2027 premium revenue, now outlined at no less than $45 billion.
- 31 December 2026: End of the fourth quarter, including the Florida Medicaid contract start-up. Guidance carries a $1.50-per-share start-up loss; a larger one pushes full-year adjusted EPS toward the $5.25 floor.
- ~5 February 2027 (est.): Fourth-quarter and full-year 2026 results and formal 2027 guidance. Tests whether the at-least-$5.25 floor held and whether 2027 guidance matches the more-than-$9.50 building blocks.
What would change the view
A daily close above $242.88, the highest close of the last 126 sessions (13 July 2026), would show the shares leading the S&P 500 and prove this call wrong.
What it trades with
Molina trades with the Medicaid-heavy managed care group. Centene rose 12.6% on 4 November 2026, the same day Molina rose 8.9% (Trefis). Policy news on Medicaid funding, eligibility and state expansion moves both. Medicare Advantage and Marketplace exposure link Molina to the wider insurer group, including cost-trend comments from larger peers. The shares do not track AI or broad growth-stock moves; Trefis noted the S&P 500 fell 1.6% from 6 October to 4 November 2026 while Molina gained 16.0%.
The evidence, claim by claim (8)
- Q3 2026 adjusted EPS $0.89 vs $0.74 estimate; revenue $11.082B vs $10.808B estimate; GAAP EPS $0.73, down 52%. Molina Q3 2026 results release (Form 8-K) · as of
- FY2026 guidance reaffirmed: adjusted EPS at least $5.25, GAAP EPS at least $2.38, premium revenue about $42 billion. Molina Form 8-K · as of
- Q3 medical cost ratio 92.9% consolidated (92.6% a year earlier); Medicaid 93.0%, Medicare 93.0%, Marketplace 92.5%. Molina Form 8-K · as of
- Guidance includes a $1.50-per-share Florida Medicaid start-up loss in Q4 and a $1.00-per-share loss from the traditional MAPD product to be exited for 2027. Molina Form 8-K · as of
- Parent-company cash and investments about $608M; no common stock repurchased in the first nine months of 2026. Molina Form 8-K · as of
- Preliminary 2027 premium outlook at least $45B (from $46.5B); building blocks exceed $9.50 of adjusted EPS without Medicaid margin improvement. Molina executive remarks, Q3 2026 earnings call · as of
- Post-report targets: J.P. Morgan $225 (Neutral), UBS $225 (Neutral), RBC $222 (Sector Perform), Morgan Stanley $192 (Equal-weight), Barclays $178 (Underweight). Analyst notes reported 23 October 2026 and 27 October 2026 · as of
- Shares rose 8.9% on 4 November 2026 after midterm election results lifted Medicaid insurers; Centene gained 12.6% that day. Trefis, 5 November 2026 · as of
Sources
- Did The Market Read Molina Healthcare Stock Right? · trefis.com ·
- Last10K ·
Related · shared themes
AGL
agilon health
agilon health roughly doubled its 2026 adjusted EBITDA guidance to $145–$155 million after a second profitable quarter, giving the shares a…
BTSG
BrightSpring Health Services
BrightSpring Health Services is growing profit faster than revenue, with third-quarter 2026 adjusted EBITDA up 42% on specialty pharmacy…
TDOC
Teladoc Health
Teladoc Health's Q3 2026 beat and fast-growing BetterHelp insurance revenue give the shares a modest edge over the S&P 500. The refinancing…
UNH
UnitedHealth Group
UnitedHealth Group's earnings recovery, with 2026 adjusted EPS guided to at least $20.50 and a buyback widened by 50 million shares, gives…